Ownership and insider activity for Arcturus Therapeutics Holdings Inc. (ARCT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations.
Price
| Price | $15.60 |
| Market Cap | $443M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-05 | HOLMES EDWARD W | A-Award | 15,000 | $110K |
| 2026-06-05 | FARRELL PETER C | A-Award | 15,000 | $110K |
| 2026-06-05 | BARLOW JAMES F | A-Award | 15,000 | $110K |
| 2026-06-05 | Markels John | A-Award | 15,000 | $110K |
| 2026-06-05 | Slaoui Moncef | A-Award | 15,000 | $110K |
| 2026-06-05 | Marquet Magda | A-Award | 15,000 | $110K |
| 2026-06-05 | Marantz Jing L. | A-Award | 15,000 | $110K |
| 2026-05-01 | MULROY DENNIS | A-Award | 100,000 | $863K |
| 2026-05-01 | MULROY DENNIS | |||
| 2025-12-17 | Roberts Joseph | A-Award | 10,000 | $65K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.3M | $25.0M | $36.7M | $71.4M | $462.9M | $370.5M | $391.9M | $292.0M | $237.0M | $230.9M |
| Short-term Investments | $47.9M | $23.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $3.6M | $480000 | $4.5M | $2.2M | $2.1M | $3.4M | $2.8M | $32.1M | $4.0M | $5.6M |
| Inventory | -$521000 | $1.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $51.3M | $50.9M | $41.8M | $74.3M | $467.8M | $379.0M | $403.3M | $386.6M | $306.0M | $241.4M |
| Property, Plant & Equipment | $240000 | $1.0M | $2.0M | $7.5M | $8.6M | $11.3M | $45.0M | $40.9M | $36.2M | $27.8M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $51.6M | $52.0M | $44.2M | $82.1M | $476.5M | $392.8M | $450.4M | $429.4M | $344.1M | $271.1M |
| Accounts Payable | $3.4M | $1.8M | $2.4M | $5.8M | $10.8M | $10.1M | $7.4M | $5.3M | $7.2M | $4.2M |
| Short-term Debt | $133000 | 0 | 0 | 0 | $1.2M | $22.5M | $60.7M | 0 | 0 | 0 |
| Total Current Liabilities | $4.3M | $11.0M | $12.6M | $21.3M | $49.5M | $99.5M | $127.0M | $82.0M | $65.5M | $36.4M |
| Long-term Debt | 0 | 0 | $9.9M | $15.0M | $13.8M | $40.6M | 0 | 0 | 0 | 0 |
| Total Liabilities | $4.3M | $18.2M | $30.6M | $56.4M | $79.9M | $164.6M | $180.1M | $150.9M | $103.1M | $57.2M |
| Retained Earnings | -$95.6M | -$23.1M | -$44.9M | -$71.7M | -$143.8M | -$347.5M | -$338.1M | -$367.9M | -$448.8M | -$514.6M |
| Total Equity | $47.2M | $33.8M | $13.6M | $25.8M | $396.6M | $228.2M | $270.3M | $278.5M | $241.0M | $214.0M |
| Total Debt | $133000 | 0 | $9.9M | $20.7M | $20.8M | $69.1M | $94.8M | $30.2M | $28.6M | $25.0M |
| Net Debt | -$50.1M | -$48.6M | -$26.8M | -$50.7M | -$442.1M | -$301.3M | -$297.1M | -$261.8M | -$208.5M | -$205.9M |
| Working Capital | $47.0M | $39.8M | $29.3M | $53.0M | $418.3M | $279.4M | $276.3M | $304.6M | $240.5M | $205.1M |
Financial Health
| Debt / Equity | 0.13 |
| Current Ratio | 5.88 |
Profitability
| Return on Equity | -46.54% |
| Return on Invested Capital | -52.96% |
| Return on Assets | -41.58% |
| Gross Margin | 83.19% |
| Operating Margin | -433.36% |
| Net Margin | -391.90% |
Related companies: ACHV · AVIR · FHTX · HUMA · IMRX · SGMT · TRDA
Explore sector: Healthcare · Biotechnology
More sections of ARCT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks